(Medscape) – About a third of people eligible for glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications for weight loss via the products’ labels would have been excluded from the clinical trials that supported their safety and effectiveness, thereby creating the potential for harm, new research suggests. (Read More)